The focus of drug development in Alzheimer's disease has increasingly been on earlier disease stages, before overt dementia, when it is difficult to assess cognitive impairment. The FDA has now developed guidance for the design and execution of relevant clinical trials.
No takes yet. Share an insight, caveat, or question.
Kozauer et al. (2013) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: